Background:
Randall Kaye, M.D. serves as Chief Medical Officer at Neurana Pharmaceuticals, a clinical-stage, biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the neck and back. As Chief Medical Officer, he leads the clinical development of tolperisone, the company’s novel, non-opioid treatment for acute and painful muscle spasms without drowsiness or impact on cognitive function.

Significant Contributions and Achievements:
Most recently, Dr. Kaye is Chief Medical Officer at Neurana Pharmaceuticals. From 2018-2019, Dr. Kaye was Chief Medical Officer at Click Therapeutics, Inc. From 2016-2018, Dr. Kaye was Chief Science Officer at SSI Strategy. From 2014-2016, Dr. Kaye was Chief Medical Officer at Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. Prior to joining Axsome, Dr. Kaye was Chief Medical Officer at Avanir Pharmaceuticals (acquired by Otsuka), a CNS specialty company. While at Avanir, Dr. Kaye designed, developed and built the clinical, regulatory and medical affairs departments, resulting in the approval and launch of a first in class neurologic therapeutic.
 

Education:
Dr. Kaye earned his Doctor of Medicine, Masters in Public Health and Bachelor of Science degrees at The George Washington University in Washington, D.C. Dr. Kaye trained in Pediatrics at the University of Massachusetts Medical School and was a Research Fellow at Harvard Medical School.

​

​

​

​

Click here to view Dr. Kaye's LinkedIn profile